← Back to Clinical Trials
Recruiting NCT06838806

NCT06838806 Epigenetic Nucleosomes in Plasma for Pulmonary Nodule Differentiation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06838806
Status Recruiting
Phase
Sponsor National Taiwan University Hospital
Condition Lung Nodule
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2025-03-11
Primary Completion 2026-03-31

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
blood draw

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2025-03-11 with a primary completion date of 2026-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Investigators aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT). Additionally, investigators will investigate the potential role of Nu.Q in lung cancer prevention and its impact on survival outcomes. Study Method: Investigators plan to collect 20 mL of blood samples from individuals undergoing chest LDCT/CT, isolate plasma for Nu.Q™ analysis, and compare the results with corresponding lung cancer pathology findings. The estimated sample size is 500 participants.

Eligibility Criteria

Inclusion Criteria: * Aged 20 or older * Underwent a low-dose chest CT scan or a standard chest CT scan, showing lung nodules ≥ 6mm * Individuals understand the content of the consent form and are willing to participate in this study. * The lung nodule is assessed by a physician as high-risk, requiring thoracic surgery or biopsy for diagnosis Exclusion Criteria: * Pregnant women * Individuals without capacity for consent, unable to understand the content of the consent form, or unwilling to participate in this study * Assessed by a physician as unsuitable for thoracic surgery or biopsy for diagnosis

Contact & Investigator

Central Contact

Pei-Hsing Chen, MD

✉ chenph@ntu.edu.tw

📞 886-2-2312-3456 Ext. 53422

Frequently Asked Questions

Who can join the NCT06838806 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, studying Lung Nodule. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06838806 currently recruiting?

Yes, NCT06838806 is actively recruiting participants. Contact the research team at chenph@ntu.edu.tw for enrollment information.

Where is the NCT06838806 trial being conducted?

This trial is being conducted at Taipei, Taiwan.

Who is sponsoring the NCT06838806 clinical trial?

NCT06838806 is sponsored by National Taiwan University Hospital. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology